To join a endometrial cancer clinical trial in United States, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in United States directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.

What phases are endometrial cancer trials in United States?

Active endometrial cancer trials in United States span Phase 2, Phase 3, Phase 1, Phase 2, EARLY_Phase 1, Phase 1. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.

Browse More

All United States Trials → Global endometrial cancer Trials → All Countries → All Trials →

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology

Active Trials in United States (25)

Study of EV for Recurrent Endometrial Carcinoma

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

A Beta-only IL-2 ImmunoTherapY Study

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Frequently Asked Questions